- Home
- SIGA vs CBLL Comparison
SIGA vs CBLL Comparison
Compare SIGA & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- CBLL
- Stock Information
- Founded
- SIGA 1995
- CBLL 2014
- Country
- SIGA United States
- CBLL United States
- Employees
- SIGA N/A
- CBLL N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- CBLL
- Sector
- SIGA Health Care
- CBLL
- Exchange
- SIGA Nasdaq
- CBLL Nasdaq
- Market Cap
- SIGA 515.1M
- CBLL 433.7M
- IPO Year
- SIGA 1997
- CBLL 2024
- Fundamental
- Price
- SIGA $8.87
- CBLL $12.56
- Analyst Decision
- SIGA
- CBLL Strong Buy
- Analyst Count
- SIGA 0
- CBLL 6
- Target Price
- SIGA N/A
- CBLL $33.00
- AVG Volume (30 Days)
- SIGA 506.6K
- CBLL 257.2K
- Earning Date
- SIGA 11-06-2025
- CBLL 11-11-2025
- Dividend Yield
- SIGA 6.77%
- CBLL N/A
- EPS Growth
- SIGA N/A
- CBLL N/A
- EPS
- SIGA 1.14
- CBLL N/A
- Revenue
- SIGA $179,639,422.00
- CBLL $77,419,000.00
- Revenue This Year
- SIGA N/A
- CBLL $35.45
- Revenue Next Year
- SIGA $115.06
- CBLL $28.18
- P/E Ratio
- SIGA $7.78
- CBLL N/A
- Revenue Growth
- SIGA 3.86
- CBLL 42.16
- 52 Week Low
- SIGA $4.95
- CBLL $10.01
- 52 Week High
- SIGA $9.62
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- SIGA 56.96
- CBLL 53.30
- Support Level
- SIGA $8.56
- CBLL $11.30
- Resistance Level
- SIGA $9.16
- CBLL $12.23
- Average True Range (ATR)
- SIGA 0.31
- CBLL 0.52
- MACD
- SIGA -0.03
- CBLL 0.19
- Stochastic Oscillator
- SIGA 68.82
- CBLL 97.19
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.